Anti-Coagulants - Gambia

Gambia

The revenue in the Anti-Coagulants market in Gambia is estimated to reach US$162.70k in 2024.
It is projected to exhibit a Compound Annual Growth Rate (CAGR 2024-2029) of 7.49%, leading to a market volume of US$233.50k by 2029.
Among all countries, United States is anticipated to generate the highest revenue, amounting to US$16,740.00m in 2024.
The demand for anti-coagulants in Gambia is steadily increasing due to the rising prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Gambia has been witnessing steady growth in recent years.

Customer preferences: Patients suffering from cardiovascular diseases and other related conditions are the primary customers of anti-coagulants in Gambia. The market is dominated by a few multinational pharmaceutical companies, and their products are preferred due to their established brand image and efficacy.

Trends in the market: The market for anti-coagulants in Gambia is expected to grow in the coming years due to the rising incidence of cardiovascular diseases. The increasing awareness about the benefits of early diagnosis and treatment of these diseases is also contributing to the growth of the market. In addition, the government's efforts to improve healthcare infrastructure and increase access to essential medicines are expected to further boost the market.

Local special circumstances: Gambia is a small country with a predominantly rural population. The healthcare infrastructure in the country is underdeveloped, and access to essential medicines is limited, especially in rural areas. The government is taking steps to improve healthcare facilities and increase access to essential medicines, but progress has been slow due to limited resources.

Underlying macroeconomic factors: The Gambian economy has been growing steadily in recent years, driven by the services sector, which accounts for a significant share of the country's GDP. However, the economy remains heavily dependent on agriculture, which employs a large share of the population. The country is also heavily reliant on imports for essential goods, including medicines, which makes it vulnerable to external shocks. The government's efforts to diversify the economy and improve infrastructure are expected to support long-term growth and development.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.